Key Points Question What are the efficacy and safety of bicistronic CD19/CD22 chimeric antigen receptor (CAR) T-cell therapy in children with relapsed or refractory acute lymphoblastic leukemia? Findings In this phase 2 nonrandomized clinical trial, bicistronic CD19/CD22 CAR T-cell therapy induced minimal residual disease–negative remission in most patients and was associated with favorable event-free survival in hematologic and isolated extramedullary relapse.
Ching-Hon Pui
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ching-Hon
Contact Ching-Hon, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack